Allergan Receives Positive Opinions for COMBIGAN(TM) from 21 Countries in European Union

Allergan, Inc. (NYSE:AGN) today announced that itreceived positive opinions for COMBIGAN(TM), Allergan'sALPHAGAN(R)/timolol combination product for glaucoma (brimonidinetartrate/timolol ophthalmic solution), from all twenty-one ConcernedMember States included in the COMBIGAN(TM) Mutual RecognitionProcedure (MRP) for the European Union. Allergan received notificationof the positive opinions for COMBIGAN(TM) from the Medicines andHealthcare products Regulatory Agency (MHRA) in the United Kingdom,which acted as the Reference Member State for the MRP. Marketingauthorization and national licenses for COMBIGAN(TM) are expected tobe issued in the coming months following each country's assessment ofthe local product labeling making COMBIGAN(TM) available in allcountries of the European Union.

COMBIGAN(TM) is indicated for reduction of intraocular pressure(IOP) in patients with chronic open-angle glaucoma or ocularhypertension who are insufficiently responsive to topicalbeta-blockers.

"We are extremely pleased by the successful conclusion of themutual recognition procedure for COMBIGAN(TM), which allows us to makethis valuable medicine available to glaucoma patients throughout theEuropean Union," said Dr. Scott Whitcup, Allergan's Executive VicePresident, Research & Development.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is atechnology-driven, global health care company providing specialtypharmaceutical products worldwide. Allergan develops andcommercializes products in the eye care, neuromodulator, skin care andother specialty markets that deliver value to its customers, satisfyunmet medical needs, and improve patients' lives.

Forward-Looking Statements

This press release contains "forward-looking statements,"including, among other statements, the statements by Dr. Whitcup,statements regarding research and development outcomes, efficacy, andmarket and product potential. These statements are based on currentexpectations of future events. If underlying assumptions proveinaccurate or unknown risks or uncertainties materialize, actualresults could vary materially from Allergan's expectations andprojections. Risks and uncertainties include general industry andpharmaceutical market conditions; general domestic and internationaleconomic conditions, such as interest rate and currency exchange ratefluctuations; technological advances and patents obtained bycompetitors; challenges inherent in product marketing such as theunpredictability of market acceptance for new pharmaceutical andbiologic products and/or the acceptance of new indications for suchproducts; domestic and foreign health care reforms; the timing anduncertainty of the research and development and regulatory processes;trends toward managed care and health care cost containment; andgovernmental laws and regulations affecting domestic and foreignoperations. Allergan expressly disclaims any intent or obligation toupdate these forward-looking statements except as required to do so bylaw.

Additional information concerning these and other risk factors canbe found in press releases issued by Allergan, as well as Allergan'spublic periodic filings with the Securities and Exchange Commission,including the discussion under the heading "Certain Factors and TrendsAffecting Allergan and its Businesses" in Allergan's 2004 Form 10-Kand Allergan's Form 10-Q for the quarter ended June 24, 2005. Copiesof Allergan's press releases and additional information about Allerganis available on the World Wide Web at www.allergan.com or you cancontact the Allergan Investor Relations Department by calling1-714-246-4636.